Scarica l'app Stockscreener
49.16
1.42%
-0.745
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$49.90
Aprire:
$50.25
Volume 24 ore:
713.55K
Relative Volume:
0.34
Capitalizzazione di mercato:
$6.07B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-11.59
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
-2.73%
1M Prestazione:
+29.45%
6M Prestazione:
+56.81%
1 anno Prestazione:
+67.37%
Intervallo 1D:
$48.07
$50.33
Intervallo di 1 settimana:
$47.45
$51.15
Portata 52W:
$20.14
$52.92
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
49.16 | 6.07B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
411.80 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.99 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
528.09 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.39 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
157.74 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing
Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine
Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director sells shares worth $157,573 - Investing.com
Guardant Health Executives Sell Shares - TradingView
Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Guardant Health (NASDAQ:GH) Given New $65.00 Price Target at Mizuho - MarketBeat
(GH) Investment Report - news.stocktradersdaily.com
Mizuho raises Guardant Health price target on positive Shield test outlook - Investing.com Canada
Guardant Health (GH) Price Target Raised to $65 by Mizuho | GH S - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Receives $53.29 Consensus PT from Analysts - MarketBeat
Guardant Health Wins Fast Company's 2025 World Changing Ideas Aw - GuruFocus
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening | GH Stock News - GuruFocus
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening - Yahoo Finance
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility - The ASCO Post
Insider Sell: Amirali Talasaz Sells 119,284 Shares of Guardant H - GuruFocus
Guardant Health Inc (GH) Shares Up 4.04% on Jun 9 - GuruFocus
Guardant Health at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer - BioSpace
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer | GH Stock News - GuruFocus
ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | G - GuruFocus
Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN
Insider Sell: Kumud Kalia Sells 4,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Inc (GH) Shares Up 3.5% on Jun 5 - GuruFocus
Mackenzie Financial Corp Has $230,000 Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Shares Climb on FDA Breakthrough Status for Cancer Detection Test - MSN
Minimal Residual Disease Testing Market Set to Witness - openPR.com
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
ARK Investment Acquires 99.6K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant - Investing.com Australia
Cathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and Guardant By Investing.com - Investing.com UK
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Guardant Health gets FDA breakthrough device status for cancer detection test - MSN
Guardant Health’s MCD test earns FDA breakthrough designation - Yahoo
111 Capital Purchases Shares of 8,303 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health’s cancer test earns FDA breakthrough status By Investing.com - Investing.com South Africa
Leerink Partners maintains outperform rating for Guardant Health stock By Investing.com - Investing.com Canada
ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Guardant Health (GH) Stock Surges on FDA Breakthrough Designatio - GuruFocus
Why Guardant Health Stock Surged Nearly 9% Higher Today - MSN
NCCN Adds 2 Tests to CRC Screening Guidelines - OncLive
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?Guardant Health (NASDAQ:GH) - Benzinga
Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa
Guardant Health shares rise following FDA breakthrough designation - Investing.com
Guardant Health (GH) Gains as FDA Grants Breakthrough Designatio - GuruFocus
Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com
Guardant Health’s cancer test earns FDA breakthrough status - Investing.com
Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.09%
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):